What is the outlook for ampicillin trihydrate amid China's drug price reform wave?

What is the outlook for ampicillin trihydrate amid China's drug price reform wave?
China's 2025 price rectification campaign is reshaping the pharmaceutical landscape, with hundreds of products facing significant price cuts. While ampicillin trihydrate itself is not explicitly listed in recent adjustments, the broader trend is clear: provincial price linkage mechanisms are squeezing high-margin drugs. For example, amikacin sulfate injections dropped from RMB 19.8 to 1.5 per vial, a 92% cut. This pressure extends to antibiotics and other mature APIs. For ampicillin trihydrate, which is largely used in oral and veterinary formulations, the risk is twofold: downstream formulation price caps compress margins for API buyers, while upstream penicillin feedstock costs remain relatively sticky. Producers may need to optimize enzymatic processes or consolidate capacity to maintain profitability. The regulatory push favors scale-efficient, vertically integrated manufacturers over small players.